hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06375174 id: NSISTRCR_2202 briefTitle: PRECISE (PERFUSION IMAGING TO IDENTIFY POSTERIOR CIRCULATION CANDIDATES FOR THROMBECTOMY) acronym: SWISS-PRECISE overallStatus: ACTIVE_NOT_RECRUITING date: 2024-01-09 date: 2026-02-28 date: 2026-02-28 date: 2024-04-19 date: 2024-04-19 name: Dr. med. Carlo Cereda class: OTHER_GOV briefSummary: We hypothesize that patients with a favorable Critical Area Perfusion Score (CAPS≤3) on cerebral perfusion imaging will have a favorable response to revascularization by thrombectomy and that patients with a CAPS\>3 will not conditions: Posterior Circulation Acute Ischemic Stroke Due to Large Vessel Occlusion of the Vertebral or Basilar Artery Needing Endovascular Thrombectomy studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 120 type: ESTIMATED name: Thrombectomy measure: mRS score sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Neurocenter of Southern Switzerland, Ospedale Civico city: Lugano state: Ticino zip: CH-6900 country: Switzerland lat: 46.01008 lon: 8.96004 hasResults: False
nctId: NCT06375161 id: CD19-CN-A6 briefTitle: Anti-CD19-CAR-T Cells in Relapsed/Refractory B-cell Tumor Patients. overallStatus: RECRUITING date: 2023-12-11 date: 2025-12-10 date: 2039-12-10 date: 2024-04-19 date: 2024-04-19 name: Shanghai Tongji Hospital, Tongji University School of Medicine class: OTHER briefSummary: This study is a single-center, open-label, single-dose clinical trial of anti-CD19-CAR-T cell therapy in relapsed/refractory B-cell tumor patients after Qinglin pre-treatment.
In this study phase, a traditional "3+3" trial design is employed for dose escalation. conditions: B Cell Malignancies studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: anti-CD19-CAR-T cells measure: Incidence of dose-limiting toxicity sex: ALL minimumAge: 18 Weeks maximumAge: 70 Weeks stdAges: CHILD facility: Shanghai Tongji Hospital status: RECRUITING city: Shanghai state: Shanghai zip: 200333 country: China name: Aibin Liang role: CONTACT phone: +8618601670600 email: lab7182@tongji.edu.cn name: Ping LI role: CONTACT phone: +86 135 6418 1131 email: lilyforever@126.com lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06375148 id: Yan2024-0052 briefTitle: A Questionnaire Survey on Cognition of Enteral Nutrition Implementation in Patients Requiring Mechanical Ventilation in Prone Position overallStatus: ENROLLING_BY_INVITATION date: 2024-03-20 date: 2024-05-30 date: 2024-06-30 date: 2024-04-19 date: 2024-04-19 name: Second Affiliated Hospital, School of Medicine, Zhejiang University class: OTHER briefSummary: Prone ventilation is an important treatment for respiratory failure with intractable hypoxia, and the Corona Virus Disease 2019(COVID-19 ) outbreak has further elevated the status of prone ventilation. Early enteral nutrition (EN) is also recognised as an important measure to improve the prognosis of critically ill patients. However, the administration of enteral nutrition during prone position is still quite controversial. In this paper, we analysed the tolerance and safety of enteral nutrition in the prone position by reviewing studies before and after the COVID-19 outbreak. Key strategies to improve the tolerability of enteral nutrition in the prone position are also summarised and discussed. conditions: Enteral Nutrition conditions: Prone Position studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 200 type: ESTIMATED name: Enteral nutrition measure: A questionnaire survey on cognition of enteral nutrition implementation in patients requiring mechanical ventilation in prone position sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Second Affiliated Hospital of Zhejiang University School of Medicine city: Zhenjiang country: China lat: 32.21086 lon: 119.45508 hasResults: False
nctId: NCT06375135 id: R1MD017205 briefTitle: mHealth + e-Navigator Stepped Care on ART Adherence in Latino MSM acronym: Project STEP overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2027-03-31 date: 2027-03-31 date: 2024-04-19 date: 2024-04-19 name: Florida International University class: OTHER name: Ann & Robert H Lurie Children's Hospital of Chicago name: Care Resource Community Health Centers briefSummary: The goal of this study is to evaluate the efficacy of stepped care strategies to improve ART adherence among adult Latino MSM with HIV using a sequential, multiple assignment, randomized trial (SMART). The trial will compare a stepped care strategy of delivering TXTXT ("Treatment Text") first and stepping up to remote patient navigation for non-responders vs. a stepped care strategy of delivering TXTXT + e-Navigation first and stepping up to EMA-supported e-Navigation for non-responders. Both TXTXT and the foundations of the e-Navigation interventions are CDC evidence-based interventions (EBI). We propose to use a SMART design which explicitly allows building, testing, and optimizing stepped care strategies without compromising rigor or randomization. We propose three specific aims:
Aim 1. Compare the immediate (6-month) and sustained (9- and 12-month) efficacy of two static (non-stepped) treatment regimens (TXTXT alone vs. TXTXT + e-Navigation) on ART adherence and viral suppression among Latino MSM with HIV. Hypothesis 1a. TXTXT + e-Navigation will be more efficacious than TXTXT alone. Aim 2. Compare the immediate (6-month) and sustained (9- and 12-month) efficacy of two stepped care strategies (TXTXT with added e-Navigation for non-responders vs. TXTXT + e-Navigation with added EMA support for non-responders) on ART adherence and viral suppression among Latino MSM with HIV. Hypothesis 2a: TXTXT + e-Navigation with added EMA support for non-responders at the 3-month follow-up will be more efficacious than TXTXT with added e-Navigation for non-responders at the 3-month follow-up. Aim 3. Identify baseline and time-varying moderators on the association between stepped care strategy and ART adherence and viral suppression among Latino MSM with HIV. Hypotheses 3a-c: TXTXT with added e-Navigation for non-responders will be less efficacious than TXTXT + e-Navigation with added EMA support for non-responders for individuals who are: (a) older at baseline, or report (b) substance use, or (c) symptoms of depression between baseline and the 3-month follow-up. conditions: ART Adherence studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: We will enroll 250 adults Latino MSM with HIV with suboptimal ART adherence and randomize (1:1) into two arms: TXTXT (n=125) or TXTXT + e-Navigation (n=125). Those in Arm 1 who continue to have suboptimal adherence (\<90% pills taken) at 3-months will be re-randomized (1:1) to continue TXTXT or add e-Navigation; those in Arm 2 who have suboptimal adherence will be re-randomized (1:1) to continue TXTXT + e-Navigation or add EMA support. At 6-months, the intervention arms will cease to receive any intervention components and be followed for an additional 6-months. primaryPurpose: TREATMENT masking: NONE count: 250 type: ESTIMATED name: TXTXT name: e-Navigation name: Ecological Momentary Assessment (EMA) supported e-Navigation. measure: ART adherence measure: HIV viral load sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Care Resource Community Health Centers, Inc., d/b/a CARE RESOURCE city: Miami state: Florida zip: 331370000 country: United States name: Sheryl J Zayas, MD role: CONTACT phone: 305-576-1234 email: szayas@careresource.org name: Sheryl J Zayas, MD role: PRINCIPAL_INVESTIGATOR lat: 25.77427 lon: -80.19366 hasResults: False
nctId: NCT06375122 id: 10001951 id: 001951-C briefTitle: Natural History Study of Kaposi Sarcoma overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2034-12-31 date: 2036-12-31 date: 2024-04-19 date: 2024-04-26 name: National Cancer Institute (NCI) class: NIH briefSummary: Background:
Kaposi sarcoma (KS) is a type of tumor caused by the Kaposi sarcoma herpesvirus. KS usually affects the skin, but lesions can also appear in the lymph nodes, lungs and digestive tract. KS is most common in people with compromised immunity, but it also appears in otherwise healthy people. Researchers want to understand more about how KS develops, why it may recur, and how it affects the immune system and organs.
Participants will follow their standard treatment for KS during the study. conditions: Kaposi Sarcoma conditions: HIV studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED measure: To characterize the natural history of KS, including presentation, manifestation, and proportion of participants with KS with remission and recurrence by epidemiologic subtype measure: To evaluate differences in rates of KS recurrence by HIV status and CD4 T cell count measure: To evaluate the emergence of KSHV-associated inflammatory syndromes in the natural history of KS sex: ALL minimumAge: 18 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT facility: National Institutes of Health Clinical Center city: Bethesda state: Maryland zip: 20892 country: United States name: National Cancer Institute Referral Office role: CONTACT phone: 888-624-1937 email: ncimo_referrals@mail.nih.gov lat: 38.98067 lon: -77.10026 hasResults: False
nctId: NCT06375109 id: BJXK-2023-KY-53 id: NeoSCLC-001 type: OTHER domain: Beijing Chest Hospital, Capital Medical University briefTitle: PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC acronym: NeoSCLC-001 overallStatus: NOT_YET_RECRUITING date: 2024-04-16 date: 2027-04-15 date: 2029-04-15 date: 2024-04-19 date: 2024-04-19 name: Beijing Chest Hospital, Capital Medical University class: OTHER briefSummary: This is an open-label, non-randomized, controlled, single-center, phase II study to compare the efficacy and safety of neoadjuvant PD-L1/PD-1 inhibitor + chemotherapy (carboplatin/cisplatin + etoposide) with chemotherapy (carboplatin/cisplatin + etoposide) alone followed by radical surgery and adjuvant treatment as perioperative therapy in patients with limited-stage SCLC. conditions: Limited-stage Small-cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 60 type: ESTIMATED name: Tislelizumab name: Carboplatin injection name: Cisplatin injection name: Etoposide injection measure: Pathologic Complete Response (pCR) Rate measure: Major Pathologic Response (MPR) Rate measure: Event-Free Survival (EFS) measure: Overall Survival (OS) measure: Objective response rate (ORR) measure: Safety: frequency of severe adverse events sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06375096 id: Graves' disease briefTitle: Bone Mineral Density in Children With Graves' Disease overallStatus: NOT_YET_RECRUITING date: 2024-06-25 date: 2025-06-25 date: 2025-06-25 date: 2024-04-19 date: 2024-04-19 name: Assiut University class: OTHER briefSummary: to evaluate bone mineral density in children with graves' disease conditions: Bone Density, Low conditions: Bone Mineral Density in Children With Graves' Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: evaluate bone mineral density measure: bone mineral density sex: ALL minimumAge: 2 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False
nctId: NCT06375083 id: 23-1231 briefTitle: Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression overallStatus: RECRUITING date: 2024-03-20 date: 2024-12-30 date: 2024-12-30 date: 2024-04-19 date: 2024-04-19 name: VA Eastern Colorado Health Care System class: FED briefSummary: This study plans to learn more about the use of one of two self-guided online cognitive behavioral therapy courses. One is focused on symptoms of depression and one is focused on history of suicidal thoughts and behaviors. conditions: Suicide conditions: Depression studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Cognitive Behavioral Therapy for Suicide Prevention (cCBT-SP) and Cognitive Behavioral Therapy for Depression (cCBT-D) primaryPurpose: TREATMENT masking: NONE count: 472 type: ESTIMATED name: Cognitive Behavioral Therapy measure: Client Satisfaction Questionnaire measure: Internet Evaluation and Utility Questionnaire measure: Internet Impact and Effectiveness Questionnaire measure: Narrative Evaluation of Intervention Interview measure: Recruitment Rate measure: Completion of intervention measure: Beck Scale for Suicide Ideation measure: Patient Health Questionnaire-9 measure: Posttraumatic Stress Disorder Checklist-5 measure: Generalized Anxiety Disorder-7 measure: Computerized Adaptive Testing - Suicide Scale sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Eastern Colorado Health Care System status: RECRUITING city: Aurora state: Colorado zip: 80045 country: United States name: Lisa A Brenner, PhD role: CONTACT phone: 720-723-6488 email: Lisa.Brenner@va.gov name: Kelly A Stearns-Yoder, MA role: CONTACT phone: 720-723-6477 email: Kelly.Stearns@va.gov lat: 39.72943 lon: -104.83192 hasResults: False
nctId: NCT06375070 id: RMeng1 briefTitle: Anticoagulants for PFO Patients overallStatus: COMPLETED date: 2016-08 date: 2022-08 date: 2022-08 date: 2024-04-19 date: 2024-04-19 name: Xuanwu Hospital, Beijing class: OTHER briefSummary: Patients who underwent both bubble transcranial Doppler (bubble-TCD) and transoesophageal echocardiography (TEE) at our institution were consecutively enrolled in this real-world case-control study from August 2016 through August 2023. The patients were categorized into three groups based on the degree of the shunt observed: mild (3-9 bubbles), moderate (10-30bubbles), and severe (more than 30 bubbles). In cases with mild-shunt (small-size) PFO, post-procedural anticoagulation or PFO closure was administered. Subsequent to the interventions, the follow-up encompassed the recording of migraine remission, recurrent neurological incidents, instances of major bleeding, and mortality. conditions: Patent Foramen Ovale studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 277 type: ACTUAL name: PFO closure name: anticoagulant measure: whether occur recurrent stroke or migraine relief sex: ALL minimumAge: 16 Years maximumAge: 65 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06375057 id: asiamkfv49wurfpylld2m6g7cr4kz6 briefTitle: Relationship Between Acute Phase Markers and Post-operative Pain in Laparoscopic Cholecystectomy: An Observational Study overallStatus: RECRUITING date: 2023-03-03 date: 2024-02-26 date: 2025-12-31 date: 2024-04-19 date: 2024-04-19 name: University of Roma La Sapienza class: OTHER briefSummary: Many patients undergoing laparoscopic cholecystectomy are prone to developing acute and chronic post-operative pain.
* select most suitable pain relief therapy for the patient. conditions: Post Operative Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 54 type: ESTIMATED name: laparoscopic cholecystectomy measure: Relationship Between Post-operative Pain and C Reactive Protein (CRP) in Laparoscopic Cholecystectomy measure: Relationship Between Post-operative Pain and D-dimer in Laparoscopic Cholecystectomy measure: Relationship Between Post-operative Pain and Fibrinogen in Laparoscopic Cholecystectomy measure: Relationship Between Post-operative Pain and white blood cell count in Laparoscopic Cholecystectomy measure: Relationship Between Post-operative Pain and Neutrophil to Lymphocyte Ratio (NLR) in Laparoscopic Cholecystectomy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Augusto Lauro status: RECRUITING city: Roma zip: 000186 country: Italy name: Augusto Lauro role: CONTACT phone: +39 388 8663 879 email: augusto.lauro@uniroma1.it lat: 41.89193 lon: 12.51133 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2023-03-03 uploadDate: 2024-04-16T07:17 filename: Prot_SAP_000.pdf size: 179155 hasResults: False
nctId: NCT06375044 id: SIM0500-101 briefTitle: Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma overallStatus: NOT_YET_RECRUITING date: 2024-05-30 date: 2026-06-30 date: 2028-12-30 date: 2024-04-19 date: 2024-04-19 name: Jiangsu Simcere Pharmaceutical Co., Ltd. class: INDUSTRY name: Shanghai Xianxiang Medical Technology Co., Ltd. briefSummary: This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM). The trial is consisted of two parts, Part 1 (dose escalation) and Part 2 (dose optimization). In both parts, SIM0500 will be administered until disease progression, intolerable toxicity, withdraw of consent or end of trial. conditions: Relapsed or Refractory Multiple Myeloma studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 130 type: ESTIMATED name: SIM0500 measure: Dose-limiting toxicity (DLT) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences city: Tianjin state: Tianjin zip: 300000 country: China name: Yan Xu role: CONTACT email: xuyan1@ihcams.ac.cn lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06375031 id: HR011408-103 briefTitle: Comparison of HR011408 and NovoRapid® in Subjects With Diabetics overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-07-01 date: 2024-07-15 date: 2024-04-19 date: 2024-04-19 name: Jiangsu HengRui Medicine Co., Ltd. class: INDUSTRY briefSummary: The objective of the study is to compare the pharmacokinetics and pharmacodynamics between HR011408 and NovoRapid® in Subjects with Diabetics. conditions: Diabetes studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: The study was designed as a multi-center, randomized, double-blind, three-cycle crossover, positive drug control (NovoRapid ®) To compare the pharmacokinetics, pharmacodynamics, safety, and tolerability of a single injection of HR011408 or NovoRapid ® before or after a standard meal test in patients with type 1 or type 2 diabetes. primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 30 type: ESTIMATED name: HR011408 injection; HR011408 injection Placebo name: NovoRapid®; HR011408 injection Placebo name: HR011408 injection Placebo; HR011408 injection measure: Area under the serum concentration-time curve of insulin aspart measure: Area under the serum concentration-time curve of insulin aspart measure: Plasma glucose concentration measure: Number of subjects with adverse events and severity of adverse events sex: ALL minimumAge: 18 Years maximumAge: 64 Years stdAges: ADULT facility: The Second Hospital of Anhui Medical University city: Hefei state: Anhui zip: 230601 country: China name: 230601 Pan, Doctor role: CONTACT phone: 0551-65997421 email: ptr1968@163.com name: Wei Hu, Doctor role: CONTACT phone: 0551-65997421 email: ayefygcp@163.com lat: 31.86389 lon: 117.28083 hasResults: False
nctId: NCT06375018 id: OST1_011 briefTitle: Effect of the Diaphragm Stretching Technique on Nonspecific Low Back Pain overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-12 date: 2024-12 date: 2024-04-19 date: 2024-04-19 name: Escola Superior de Tecnologia da Saúde do Porto class: OTHER briefSummary: This study aims to analyze the efficacy of diaphragm stretching technique on symptomatology in young adults with nonspecific low back pain. conditions: Nonspecific Low Back Pain studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 45 type: ESTIMATED name: Placebo Technique name: Diaphragm Stretching measure: Change in level of inspiratory capacity immediately after intervention measure: Change in the level of disability derived from low back pain immediately after the intervention measure: Change in the level of functionality of the lumbar spine immediately after the intervention sex: ALL minimumAge: 18 Years maximumAge: 30 Years stdAges: ADULT facility: Escola Superior de Saúde do Porto city: Porto zip: 4200-072 country: Portugal lat: 41.14961 lon: -8.61099 hasResults: False
nctId: NCT06374992 id: Pro00114569 briefTitle: Family Involvement Hospital Ethnography overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-08 date: 2024-08 date: 2024-04-19 date: 2024-04-19 name: Duke University class: OTHER briefSummary: The goal of this observational study is to learn about the role of family members in caring for hospitalized older adults with cognitive impairment. The main questions it aims to answer are:
Data collection will occur via semi-structure interviews, direct observation, and artifact analysis. conditions: Dementia studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 40 type: ESTIMATED measure: Faciltators and Barriers to Family Involvement in Care of Hospitalized Older Adults with Cognitive Impairment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06374979 id: 2024-0047 briefTitle: Efficacy and Safety of Ixekizumab in Patients With Refractory Guttate Psoriasis overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2024-10 date: 2025-06 date: 2024-04-19 date: 2024-04-19 name: Second Affiliated Hospital, School of Medicine, Zhejiang University class: OTHER briefSummary: The goal of this clinical trial is to analyse efficacy and safety of ixekizumab in participants with refractory guttate psoriasis. The main question it aims to answer is:
What percentage of participants achieved more than 90% reduction from baseline in Psoriasis Area Index （PASI 90） after 12 weeks of ixekizumab treatment? Participants will receive a 12-week treatment of ixekizumab, with follow-up visits every 2 weeks during the treatment period. Keep a diary of their symptoms and Psoriasis Area Index. conditions: Guttate Psoriasis studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: Ixekizumab measure: PASI 90 response measure: PGA 0/1 response measure: PASI 100 response measure: Relapse sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06374953 id: 2024-0182 briefTitle: A Novel Viscoelastic Test Based on Ultrasonic Guided Wave for Identifying Hyperfibrinolysis Rapidly overallStatus: RECRUITING date: 2024-03-26 date: 2024-09-30 date: 2024-09-30 date: 2024-04-19 date: 2024-04-19 name: Second Affiliated Hospital, School of Medicine, Zhejiang University class: OTHER briefSummary: This study compares the results of the existing fibrinolysis monitoring technology to the Ultrasound-based viscoelastic hemostasis analysis, a new method, using small amount of extra blood obtained during routine blood draws in surgery patients. conditions: Hyperfibrinolysis studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: PROSPECTIVE count: 140 type: ESTIMATED name: Ultrasound-based viscoelastic hemostasis analysis measure: Comparison of the novel viscoelastic hemostasis analysis results to TEG-LY30 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Second Affiliated Hospital of Zhejiang University anesthesiology department status: RECRUITING city: Hangzhou state: Zhejiang zip: 310009 country: China name: Fengjiang ZHANG role: CONTACT phone: +8613858007629 email: zrzfj@zju.eud.cn lat: 30.29365 lon: 120.16142 hasResults: False